RESULTS: These adjustments were applied to data from a randomized double-blind concurrent trial (SPD __number__ ) that established the efficacy and safety of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).